For: | Spadi R, Brusa F, Ponzetti A, Chiappino I, Birocco N, Ciuffreda L, Satolli MA. Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians. World J Clin Oncol 2016; 7(1): 27-43 [PMID: 26862489 DOI: 10.5306/wjco.v7.i1.27] |
---|---|
URL: | https://www.wjgnet.com/2150-5330/full/v7/i1/27.htm |
Number | Citing Articles |
1 |
Chunhui Nie, Yuelin Zhang, Guanhui Zhou, Tanyang Zhou, Tongyin Zhu, Baoquan Wang, Shengqun Chen, Hongliang Wang, Ziniu Yu, Li Jing, Junhui Sun. Analysis of the efficacy of transcatheter arterial infusion chemotherapy in the treatment of pancreatic carcinoma. Journal of Interventional Medicine 2021; 4(1): 21 doi: 10.1016/j.jimed.2020.10.005
|
2 |
Jaeyun Jung, Cue Hyunkyu Lee, Hyang Sook Seol, Yeon Sook Choi, Eunji Kim, Eun Ji Lee, Je-Keun Rhee, Shree Ram Singh, Eun Sung Jun, Buhm Han, Seung Mo Hong, Song Cheol Kim, Suhwan Chang. Generation and molecular characterization of pancreatic cancer patient-derived xenografts reveals their heterologous nature. Oncotarget 2016; 7(38): 62533 doi: 10.18632/oncotarget.11530
|
3 |
Zensho Ito, Shin Kan, Tsuuse Bito, Sankichi Horiuchi, Takafumi Akasu, Sayumi Yoshida, Mikio Kajihara, Atsushi Hokari, Masayuki Saruta, Noriyuki Yoshida, Masanori Kobayashi, Toshifumi Ohkusa, Shigetaka Shimodaira, Masato Okamoto, Haruo Sugiyama, Shigeo Koido. Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1. Oncology 2019; 97(3): 135 doi: 10.1159/000500359
|
4 |
Ugo Soffientini, Annette Graham. Intracellular cholesterol transport proteins: roles in health and disease. Clinical Science 2016; 130(21): 1843 doi: 10.1042/CS20160339
|
5 |
Fan Lei, Xinyuan Xi, Surinder K. Batra, Tatiana K. Bronich. Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer. Journal of Pharmacology and Experimental Therapeutics 2019; 370(3): 682 doi: 10.1124/jpet.118.255786
|
6 |
Aesha I. Ali, Amanda J. Oliver, Tinaz Samiei, Jack D. Chan, Michael H. Kershaw, Clare Y. Slaney. Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer. Frontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.00056
|
7 |
Sriram Anbil, Michael Pigula, Huang-Chiao Huang, Srivalleesha Mallidi, Mans Broekgaarden, Yan Baglo, Pushpamali De Silva, Diane M. Simeone, Mari Mino-Kenudson, Edward V. Maytin, Imran Rizvi, Tayyaba Hasan. Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy. Molecular Cancer Therapeutics 2020; 19(6): 1308 doi: 10.1158/1535-7163.MCT-19-0791
|
8 |
Zhennan Yun, Fanqi Meng, Shiquan Li, Ping Zhang. Long non-coding RNA CERS6-AS1 facilitates the oncogenicity of pancreatic ductal adenocarcinoma by regulating the microRNA-15a-5p/FGFR1 axis. Aging 2021; 13(4): 6041 doi: 10.18632/aging.202540
|
9 |
Serena Veschi, Laura De Lellis, Rosalba Florio, Paola Lanuti, Alberto Massucci, Nicola Tinari, Michele De Tursi, Pierluigi di Sebastiano, Marco Marchisio, Clara Natoli, Alessandro Cama. Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells. Journal of Experimental & Clinical Cancer Research 2018; 37(1) doi: 10.1186/s13046-018-0904-2
|
10 |
Fang Xie, Mei Huang, Xiansheng Lin, Chenhai Liu, Zhen Liu, Futao Meng, Chao Wang, Qiang Huang. RETRACTED ARTICLE: The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-26496-0
|
11 |
Susanna Hegewisch‐Becker, Ali Aldaoud, Thomas Wolf, Beate Krammer‐Steiner, Hartmut Linde, Renate Scheiner‐Sparna, David Hamm, Martina Jänicke, Norbert Marschner. Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma. International Journal of Cancer 2019; 144(5): 981 doi: 10.1002/ijc.31751
|
12 |
Amir Hossein Daneshmanesh, Mohammad Hojjat-Farsangi, Amineh Ghaderi, Ali Moshfegh, Lotta Hansson, Johan Schultz, Jan Vågberg, Styrbjörn Byström, Elisabeth Olsson, Thomas Olin, Anders Österborg, Håkan Mellstedt, Aamir Ahmad. A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib. PLOS ONE 2018; 13(6): e0198038 doi: 10.1371/journal.pone.0198038
|
13 |
Louisa Stern, Lukas Boehme, Mara Goetz, Christine Nitschke, Anastasios Giannou, Tao Zhang, Cenap Güngör, Matthias Reeh, Jakob Izbicki, Ralf Fliegert, Anne Hausen, Nathalia Giese, Thilo Hackert, Masha Niv, Stefan Heinrich, Matthias Gaida, Tarik Ghadban. Potential role of the bitter taste receptor T2R14 in the prolonged survival and enhanced chemoresponsiveness induced by apigenin. International Journal of Oncology 2022; 62(1) doi: 10.3892/ijo.2022.5454
|
14 |
Roseane Guimarães Ferreira, Luis Eduardo Mosquera Narvaez, Kaio Murilo Monteiro Espíndola, Amanda Caroline R. S. Rosario, Wenddy Graziela N. Lima, Marta Chagas Monteiro. Can Nimesulide Nanoparticles Be a Therapeutic Strategy for the Inhibition of the KRAS/PTEN Signaling Pathway in Pancreatic Cancer?. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.594917
|
15 |
Gertrud Forika, Andrea Balogh, Tamas Vancsik, Attila Zalatnai, Gabor Petovari, Zoltan Benyo, Tibor Krenacs. Modulated Electro-Hyperthermia Resolves Radioresistance of Panc1 Pancreas Adenocarcinoma and Promotes DNA Damage and Apoptosis In Vitro. International Journal of Molecular Sciences 2020; 21(14): 5100 doi: 10.3390/ijms21145100
|
16 |
P. G. Tarazov, A. V. Kozlov, D. A. Granov, A. V. Pavlovskiy, A. A. Polikarpov, E. V. Rozengaus, S. A. Popov, E. V. Vlasova, V. E. Moiseenko. ARTERIAL CHEMOINFUSION IN PATIENTS WITH LOCALLY ADVANCED AND METASTATIC PANCREAS CANCER. Grekov's Bulletin of Surgery 2016; 175(5): 36 doi: 10.24884/0042-4625-2016-175-5-36-40
|
17 |
Feifan Zhou, Jingxuan Yang, Yuqing Zhang, Mingyang Liu, Mark L. Lang, Min Li, Wei R. Chen. Local Phototherapy Synergizes with Immunoadjuvant for Treatment of Pancreatic Cancer through Induced Immunogenic Tumor Vaccine. Clinical Cancer Research 2018; 24(21): 5335 doi: 10.1158/1078-0432.CCR-18-1126
|
18 |
Randy Yeh, Jonathan Steinman, Lyndon Luk, Michael D. Kluger, Elizabeth M. Hecht. Imaging of pancreatic cancer: what the surgeon wants to know. Clinical Imaging 2017; 42: 203 doi: 10.1016/j.clinimag.2016.10.002
|
19 |
Ching-Yao Yang, Ming Huei Fan, Carol H. Miao, Yi Jen Liao, Ray-Hwang Yuan, Chao Lien Liu. Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer. Molecular Therapy - Oncolytics 2020; 17: 571 doi: 10.1016/j.omto.2020.05.009
|
20 |
Ganji Purnachandra Nagaraju, Katerina M. Zakka, Jerome C. Landry, Walid L. Shaib, Gregory B. Lesinski, Bassel F. El‐Rayes. Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer. International Journal of Cancer 2019; 145(6): 1529 doi: 10.1002/ijc.32227
|
21 |
Derek K. Cheng, Tobiloba E. Oni, Jennifer S. Thalappillil, Youngkyu Park, Hsiu-Chi Ting, Brinda Alagesan, Nadia V. Prasad, Kenneth Addison, Keith D. Rivera, Darryl J. Pappin, Linda Van Aelst, David A. Tuveson. Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer. Proceedings of the National Academy of Sciences 2021; 118(21) doi: 10.1073/pnas.2016904118
|
22 |
Hongchao Han, Lisheng Wang, Jie Xu, Aikun Wang. miR‑128 induces pancreas cancer cell apoptosis by targeting MDM4. Experimental and Therapeutic Medicine 2018; doi: 10.3892/etm.2018.6047
|
23 |
Negin Rahnama, Mohammadsaleh Jahangir, Samira Alesaeid, Mohammad Saeed kahrizi, Ali Adili, Rebar N. Mohammed, Ramin Aslaminabad, Morteza Akbari, Ali Mert Özgönül. Association between microRNAs and chemoresistance in pancreatic cancer: Current knowledge, new insights, and forthcoming perspectives. Pathology - Research and Practice 2022; 236: 153982 doi: 10.1016/j.prp.2022.153982
|
24 |
Avital Lev, Amriti R. Lulla, Jessica Wagner, Marie D. Ralff, Joshua B. Kiehl, Yan Zhou, Cyril H. Benes, Varun V. Prabhu, Wolfgang Oster, Igor Astsaturov, David T. Dicker, Wafik S. El-Deiry. Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP. Oncotarget 2017; 8(47): 81776 doi: 10.18632/oncotarget.20819
|
25 |
Sarah J. Hartman, Stacey M. Bagby, Betelehem W. Yacob, Dennis M. Simmons, Morgan MacBeth, Christopher H. Lieu, S. Lindsey Davis, Alexis D. Leal, John J. Tentler, Jennifer R. Diamond, S. Gail Eckhardt, Wells A. Messersmith, Todd M. Pitts. WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.642328
|
26 |
Serena Veschi, Maurizio Ronci, Paola Lanuti, Laura De Lellis, Rosalba Florio, Giuseppina Bologna, Luca Scotti, Erminia Carletti, Federica Brugnoli, Maria Cristina Di Bella, Valeria Bertagnolo, Marco Marchisio, Alessandro Cama. Integrative proteomic and functional analyses provide novel insights into the action of the repurposed drug candidate nitroxoline in AsPC-1 cells. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-59492-4
|
27 |
Bo Chen, Tuo Deng, Liming Deng, Haitao Yu, Bangjie He, Kaiyu Chen, Chongming Zheng, Daojie Wang, Yi Wang, Gang Chen. Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma. BMC Cancer 2021; 21(1) doi: 10.1186/s12885-021-08962-7
|
28 |
Chundong Cheng, Zonglin Liu, Danxi Liu, Hua Chen, Yongwei Wang, Bei Sun. LncRNA CCAT1 participates in pancreatic ductal adenocarcinoma progression by forming a positive feedback loop with c-Myc. Carcinogenesis 2024; 45(1-2): 69 doi: 10.1093/carcin/bgad076
|
29 |
Merin Joseph, Muhammed Shafeeque Rahman Pathiripparambath, Hanas Tharayil, Ramapurath S. Jayasree, Lakshmi V. Nair. Copper Nanocluster Enables Simultaneous Photodynamic and Chemo Therapy for Effective Cancer Diagnosis and Treatment in Vitro. ChemMedChem 2022; 17(19) doi: 10.1002/cmdc.202200201
|
30 |
Callum Baird Nattress, Gunnel Halldén. Advances in oncolytic adenovirus therapy for pancreatic cancer. Cancer Letters 2018; 434: 56 doi: 10.1016/j.canlet.2018.07.006
|
31 |
Navni Sharma, Vimal Arora. Strategies for drug targeting in pancreatic cancer. Pancreatology 2022; 22(7): 937 doi: 10.1016/j.pan.2022.08.001
|
32 |
Rosalba Florio, Barbara De Filippis, Serena Veschi, Viviana di Giacomo, Paola Lanuti, Giulia Catitti, Davide Brocco, Annalisa di Rienzo, Amelia Cataldi, Ivana Cacciatore, Rosa Amoroso, Alessandro Cama, Laura De Lellis. Resveratrol Derivative Exhibits Marked Antiproliferative Actions, Affecting Stemness in Pancreatic Cancer Cells. International Journal of Molecular Sciences 2023; 24(3): 1977 doi: 10.3390/ijms24031977
|
33 |
Jesse M. Mast, Dan Tse, Kevin Shee, M. Lakshmi Kuppusamy, Maciej M. Kmiec, Tamás Kálai, Periannan Kuppusamy. Diarylidenylpiperidones, H-4073 and HO-3867, Induce G2/M Cell-Cycle Arrest, Apoptosis and Inhibit STAT3 Phosphorylation in Human Pancreatic Cancer Cells. Cell Biochemistry and Biophysics 2019; 77(2): 109 doi: 10.1007/s12013-019-00873-6
|
34 |
Bo Yang, Yanni Quan, Wuli Zhao, Yingjie Ji, Xiaotang Yang, Jianrui Li, Yi Li, Xiujun Liu, Ying Wang, Yanping Li. Design, synthesis and biological evaluation of 2-((4-sulfamoylphenyl)amino)-pyrrolo[2,3-d]pyrimidine derivatives as CDK inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry 2023; 38(1) doi: 10.1080/14756366.2023.2169282
|
35 |
Shanshan Liu, Jiawen He, Ruixiang Song, Mengmeng Zhang, Lianghao Huang, Jing Chen, Meng Wang, Fang Liu, Feifan Zhou. Fe2P nanorods based photothermal therapy combined with immune checkpoint inhibitors for pancreatic cancer. Nanophotonics 2021; 10(12): 3267 doi: 10.1515/nanoph-2021-0196
|
36 |
Dimitrios Moris, Nikolaos Machairas, Diamantis I. Tsilimigras, Anastasia Prodromidou, Aslam Ejaz, Matthew Weiss, Natasha Hasemaki, Evangelos Felekouras, Timothy M. Pawlik. Systematic Review of Surgical and Percutaneous Irreversible Electroporation in the Treatment of Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology 2019; 26(6): 1657 doi: 10.1245/s10434-019-07261-7
|
37 |
Kai Xu, Yongliang Chen, Junjun Su, Ming Su, Li Yan. Irreversible electroporation and adjuvant chemoradiotherapy for locally advanced pancreatic carcinoma. Journal of Cancer Research and Therapeutics 2020; 16(2): 280 doi: 10.4103/jcrt.JCRT_773_18
|
38 |
Yanyan Hu, Chongwei Chi, Shunhao Wang, Lingxiong Wang, Ping Liang, Fangyi Liu, Wenting Shang, Weiwei Wang, Fengrong Zhang, Shanshan Li, Heyun Shen, Xiaoling Yu, Huiyu Liu, Jie Tian. A Comparative Study of Clinical Intervention and Interventional Photothermal Therapy for Pancreatic Cancer. Advanced Materials 2017; 29(33) doi: 10.1002/adma.201700448
|
39 |
Dong S., Wang L., Guo Y. B., Ying H. F., Shen X. H., Meng Z. Q., Chen Hao, Chen Q. W., Li Z. S.. Risk factors of liver metastasis from advanced pancreatic adenocarcinoma: a large multicenter cohort study. World Journal of Surgical Oncology 2017; 15(1) doi: 10.1186/s12957-017-1175-7
|
40 |
Shiwei Guo, Suizhi Gao, Rendong Liu, Jing Shen, Xiaohan Shi, Sijia Bai, Huan Wang, Kailian Zheng, Zhuo Shao, Chuanyu Liang, Siying Peng, Gang Jin. Oncological and genetic factors impacting PDX model construction with NSG mice in pancreatic cancer. The FASEB Journal 2019; 33(1): 873 doi: 10.1096/fj.201800617R
|
41 |
Eun A Choi, Yeon-Sook Choi, Eun Ji Lee, Shree Ram Singh, Song Cheol Kim, Suhwan Chang. A pharmacogenomic analysis using L1000CDS2 identifies BX-795 as a potential anticancer drug for primary pancreatic ductal adenocarcinoma cells. Cancer Letters 2019; 465: 82 doi: 10.1016/j.canlet.2019.08.002
|
42 |
Adriana Harbuzariu, Antonio Rampoldi, Danielle S Daley-Brown, Pierre Candelaria, Tia L Harmon, Crystal C Lipsey, Derrick J Beech, Alexander Quarshie, Gabriela Oprea Ilies, Ruben R Gonzalez-Perez. Leptin-Notch signaling axis is involved in pancreatic cancer progression. Oncotarget 2017; 8(5): 7740 doi: 10.18632/oncotarget.13946
|
43 |
A. V. Kozlov, D. A. Granov, P. G. Tarazov, A. V. Pavlovskiy, L. I. Korytova, A. A. Polikarpov, S. A. Popov, E. V. Rozengauz. Intra-arterial chemotherapy for advanced pancreatic cancer. Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery 2019; 24(3): 73 doi: 10.16931/1995-5464.2019373-86
|
44 |
John P. Neoptolemos, Jörg Kleeff, Patrick Michl, Eithne Costello, William Greenhalf, Daniel H. Palmer. Therapeutic developments in pancreatic cancer: current and future perspectives. Nature Reviews Gastroenterology & Hepatology 2018; 15(6): 333 doi: 10.1038/s41575-018-0005-x
|
45 |
Diamantis I. Tsilimigras, Dimitrios Moris, Timothy M. Pawlik. ASO Author Reflections: Irreversible Electroporation for Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology 2019; 26(S3): 610 doi: 10.1245/s10434-019-07436-2
|
46 |
Karin Juliane Pelizzaro Rocha-Brito, Emanuella Maria Barreto Fonseca, Breno Germano de Freitas Oliveira, Ângelo de Fátima, Carmen Veríssima Ferreira-Halder. Calix[6]arene diminishes receptor tyrosine kinase lifespan in pancreatic cancer cells and inhibits their migration and invasion efficiency. Bioorganic Chemistry 2020; 100: 103881 doi: 10.1016/j.bioorg.2020.103881
|
47 |
Shui-Fang Jin, Zhao-Kun Fan, Lei Pan, Li-Ming Jin. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials. Hepatobiliary & Pancreatic Diseases International 2017; 16(3): 236 doi: 10.1016/S1499-3872(17)60022-5
|
48 |
Zhe Pei, Wei Fu, Gongping Wang. A natural product toosendanin inhibits epithelial-mesenchymal transition and tumor growth in pancreatic cancer via deactivating Akt/mTOR signaling. Biochemical and Biophysical Research Communications 2017; 493(1): 455 doi: 10.1016/j.bbrc.2017.08.170
|
49 |
Ghaidaa Raheem Lateef Al-Awsi, Saade Abdalkareem Jasim, Yasser Fakri Mustafa, Firas Rahi Alhachami, Shukhrat Ziyadullaev, Mahmoud Kandeel, Roua Abulkassim, R Sivaraman, Noora M Hameed, Rosario Mireya Romero Parra, Sajad Karampoor, Rasoul Mirzaei. The role of miRNA-128 in the development and progression of gastrointestinal and urogenital cancer. Future Oncology 2022; 18(38): 4209 doi: 10.2217/fon-2022-0574
|
50 |
Qijun Yi, Jie Wang, Tingting Liu, Yi Yao, Ian Loveless, Kalpana Subedi, Jugmohit Toor, Indra Adrianto, Hua Xiao, Bin Chen, Howard C. Crawford, Deyu Fang, Li Zhou, Qing-Sheng Mi. scRNA-Seq and imaging mass cytometry analyses unveil iNKT cells-mediated anti-tumor immunity in pancreatic cancer liver metastasis. Cancer Letters 2023; 561: 216149 doi: 10.1016/j.canlet.2023.216149
|
51 |
Metin Uz, Manisha Kalaga, Ramesh Pothuraju, Juhyung Ju, Wade M. Junker, Surinder K. Batra, Surya Mallapragada, Satyanarayana Rachagani. Dual delivery nanoscale device for miR-345 and gemcitabine co-delivery to treat pancreatic cancer. Journal of Controlled Release 2019; 294: 237 doi: 10.1016/j.jconrel.2018.12.031
|
52 |
Jiachun Ding, Jiaqiang Ren, Fan Chen, Yangyang Yue, Chao Ren, Xirui Wang, Qingyong Ma, Zheng Wu, Zheng Wang. Prognostic Nomogram for pancreatic cancer with lung metastasis: a SEER database-based study. Journal of Pancreatology 2021; 4(1): 28 doi: 10.1097/JP9.0000000000000059
|
53 |
Arndt Vogel, Fortunato Ciardiello, Richard A. Hubner, Jean-Frédéric Blanc, Alfredo Carrato, Yoojung Yang, Dipen A. Patel, Varun Ektare, Floris A. de Jong, Sharlene Gill. Post-gemcitabine therapy for patients with advanced pancreatic cancer – A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens. Cancer Treatment Reviews 2016; 50: 142 doi: 10.1016/j.ctrv.2016.09.001
|
54 |
Yunpeng Sun, Qiandong Zhu, Mengtao Zhou, Wenjun Yang, Hongqi Shi, Yunfeng Shan, Qiyu Zhang, Fuxiang Yu. Restoration of miRNA‑148a in pancreatic cancer reduces invasion and metastasis by inhibiting the Wnt/β‑catenin signaling pathway via downregulating maternally expressed gene‑3. Experimental and Therapeutic Medicine 2018; doi: 10.3892/etm.2018.7026
|
55 |
Claire Vennin, Nicola Rath, Marina Pajic, Michael F. Olson, Paul Timpson. Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy. Small GTPases 2020; 11(1): 45 doi: 10.1080/21541248.2017.1345712
|
56 |
Kai Qu, Xing Zhang, Ting Lin, Tian Liu, Zhixin Wang, Sushun Liu, Lei Zhou, Jichao Wei, Hulin Chang, Ke Li, Zheng Wang, Chang Liu, Zheng Wu. Circulating miRNA-21-5p as a diagnostic biomarker for pancreatic cancer: evidence from comprehensive miRNA expression profiling analysis and clinical validation. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-01904-z
|
57 |
Sayumi Yoshida, Zensho Ito, Machi Suka, Tsuuse Bito, Shin Kan, Takafumi Akasu, Masayuki Saruta, Masato Okamoto, Hiroaki Kitamura, Shuichi Fujioka, Takeyuki Misawa, Tadashi Akiba, Hiroyuki Yanagisawa, Haruo Sugiyama, Shigeo Koido. Clinical Significance of Tumor-Infiltrating T Cells and Programed Death Ligand-1 in Patients with Pancreatic Cancer. Cancer Investigation 2019; 37(9): 463 doi: 10.1080/07357907.2019.1661427
|
58 |
Xiaolong Wei, Jiekun Yang, Sara J. Adair, Harun Ozturk, Cem Kuscu, Kyung Yong Lee, William J. Kane, Patrick E. O’Hara, Denis Liu, Yusuf Mert Demirlenk, Alaa Hamdi Habieb, Ebru Yilmaz, Anindya Dutta, Todd W. Bauer, Mazhar Adli. Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells. Proceedings of the National Academy of Sciences 2020; 117(45): 28068 doi: 10.1073/pnas.2009899117
|